Peroxisome proliferator-activated receptor g (PPARg) is a nuclear receptor regulating an array of diverse functions in a variety of cell types including regulation of genes associated with growth and differentiation. Its most notable function is to regulate development of adipose tissue, which involves coordinating expression of many hundreds of genes responsible for establishment of the mature adipocyte phenotype. Our recent studies have demonstrated a role for MEK/ERK signaling and CCAAT/enhancer binding proteins (C/EBP)b in regulating expression of PPARg during adipogenesis. Furthermore, we have shown that cAMP-dependent signaling along with C/EBPb leads to the stimulation of PPARg activity by mechanisms that probably involve production of PPARg ligands. Additionally, we have recently demonstrated that phosphorylation of C/EBPb at a consensus ERK/GSK3 site is required for the PPARg-associated expression of adiponectin during the terminal stages of adipogenesis. GSK3b also influences PPARg activity by regulating the turnover and subcellular localization of b-catenin, a potent transcriptional activator of Wnt signaling. In fact, we have recently shown a crosstalk between PPARg and b-catenin signaling. Specifically, activation of PPARg induces the degradation of b-catenin during preadipocyte differentiation by mechanisms that require GSK3b and the proteasome. In contrast, expression of a GSK3b-phosphorylation-defective b-catenin renders b-catenin resistant to the degradatory action of PPARg. Interestingly, expression of the mutant b-catenin blocks expression of adiponectin and C/EBPa in response to the activation of PPARg.
The differentiation of preadipocytes into mature insulinsensitive adipocytes, which produce adiponectin, is stimulated by members of two families of transcription factors, the CCAAT/enhancer binding proteins (C/EBPs) and peroxisome proliferator-activated receptors (PPARs). 1 Studies using various mouse models have shown a role for PPARg as well as C/ EBPa, C/EBPb and C/EBPd in regulating adipose tissue development in vivo. [2] [3] [4] [5] It appears that the formation of white adipose tissue is completely dependent on the presence of PPARg and C/EBPa, whereas there is some redundancy with respect to the role of C/EBPb and C/EBPd. Nevertheless, it appears that both C/EBPb and C/EBPd provide an important function in contributing to the induction of PPARg and C/EBPa expression during the initial 1-2 days of adipogenesis. [6] [7] [8] PPARg and C/EBPa crossregulate each other's expression as well as governing expression of the entire adipogenic program, which includes activation of additional transcription factors. 9 The activity of PPARg is regulated by an array of effectors including phosphorylation and association with lipophilic ligands that facilitate recruitment of coactivators. 10 Ligands for PPARg include derivatives of long-chain polyunsaturated fatty acids as well as the thiazolidinedione family of insulin sensitizers such as troglitazone; however, the endogenous ligand responsible for regulating PPARg activity during adipogenesis has not been identified. Role of signaling pathways and C/EBPb in regulating PPARc expression and activity
Exposure of confluent 3T3-L1 preadipocytes to dexamethasone (DEX), isobutylmethylxanthine (MIX), insulin and fetal bovine serum (FBS) induces a cascade of transcriptional events that involves a rapid induction of C/EBPb and C/EBPd, which precedes expression of the two master regulators of terminal adipogenesis, PPARg and C/EBPa. 12 Our previous studies have shown that the early induction of C/EBPb and C/EBPd along with glucocorticoids is responsible for the initiation of PPARg expression. 8 Expression of C/EBPa appears to depend on PPARg activity, but the precise mechanisms are not known. 13 Activation of PPARg through the production of corresponding ligands also appears to occur during this early time period and involves C/EBPb-as well as cAMP-dependent signaling. 13 Specifically, we demonstrated that culture of 3T3-L1 preadipocytes under conditions that do not stimulate cAMP signaling (ie exposure to DEX and insulin without MIX) activates expression of PPARg1, but is not capable of inducing expression of the entire adipogenic program. Interestingly, treatment of these MIX-deficient cells to a PPARg ligand, troglitazone, rescued the block in adipogenesis. Furthermore, we showed that ectopic expression of a dominant-negative isoform of C/ EBPb (LIP) also blocked adipogenesis without preventing the induction of PPARg1 by DEX. Additionally, we demonstrated that treatment of the LIP-expressing preadipocytes with troglitazone in the presence of DEX, MIX and insulin induced differentiation into adipocytes. We conclude, therefore, that C/EBPb activates a program, which leads to the synthesis of molecules that can act as activators of PPARg. This program probably involves other transcription factors such as SREBP-1c, which, as mentioned above, has previously been shown to be involved in PPARg ligand production. The role of C/EBPb in regulating PPARg expression and activity is illustrated in Figure 1 .
Phosphorylation of C/EBPb at a consensus ERK/ GSK3 site regulates its transcriptional activity
Since C/EBPb provides an important function in regulating the activity as well as the expression of PPARg during the early phase of adipogenesis, we considered it important to identify the signaling pathways controlling C/EBPb activity. Our recent studies demonstrate that hormonal stimulation of confluent 3T3-L1 preadipocytes induces a rapid but transient burst of MEK/ERK signaling that coincides with the induction of C/EBPb expression. Use of a specific inhibitor of MEK1 activity (U0126) has allowed us to demonstrate a role for MEK/ERK signaling in regulating expression of PPARg and C/EBPa. 14 Since MEK/ERK signaling and C/EBPb appear to be involved in controlling both PPARg and C/EBPa expression, we recently questioned whether MEK/ERK signaling is regulating the adipogenic activity of C/EBPb. C/EBPb is composed of a C-terminal region containing the basic DNA binding and leucine zipper domains and an N-terminal region, which contains transactivation domains. It has been suggested that C/EBPb can exist in a repressed state and is activated by the phosphorylation of a repressor region, which is located between the N-terminal transactivation domains and the DNA binding-leucine zipper region. This repressor domain contains several serines and threonines, all of which can be phosphorylated by a constitutive process. Interestingly, the site encompassing threonine 188 (SPPGT 188 PSP) in murine C/EBPb is a consensus site for ERK and GSK3 and is phosphorylated in response to exposure of 3T3-L1 preadipocytes to the adipogenic inducers. To assess the importance of phosphorylation of this site in regulating C/EBPb activity, we ectopically expressed C/EBPb (WT) as well as two mutants in which threonine 188 had been modified to either an alanine (T-A) or aspartic acid (T-D) in Swiss fibroblasts. Ectopic expression of the wild-type protein in cells exposed to DEX, MIX, insulin and FBS induced expression of PPARg, which when activated by treatment with troglitazone led to expression of the complete adipogenic program including production of abundant quantities of adiponectin. The T-A mutant of C/EBPb was also capable of inducing PPARg expression and part of the adipogenic program, but it was incapable of stimulating production of adiponectin. The T-D mutant, however, expressed an adipogenic activity similar to that of the wild-type protein. The absence of adiponectin in cells expressing the T-A mutant correlated with a significantly reduced amount of C/EBPa when compared to the wild-type cells. In fact, ectopic expression of PPARg in C/ EBPa-deficient fibroblasts was incapable of inducing expression of adiponectin, whereas expression of PPARg along with C/EBPa facilitated production of adiponectin. 15 Taken together, these observations suggest that phosphorylation of C/EBPb at a consensus MEK/GSK3 site is required for the expression of C/EBPa by PPARg and a select set of C/EBPa target genes most notably adiponectin (Figure 2 ). It is possible that C/EBPb is regulating the expression of specific
PPARγ ligands adipogenic genes Figure 1 Role of C/EBPb in regulating PPARg expression and activity.
Stimulation of C/EBPb in response to exposure of preadipocytes to adipogenic hormones induces expression of PPARg and leads to the production of PPARg ligands. Activated PPARg controls terminal adipogenesis by inducing expression of C/EBPa, which is required for the production of specific adipogenic genes.
coactivators of PPARg, which are required for the induction of C/EBPa transcription.
Role of GSK3 and b-catenin in regulating PPARc activity
In addition to being a regulator of C/EBPb and C/EBPa activity, GSK3 is also a component of the Wnt signaling pathway. Recent studies have shown that Wnt signaling appears to function during the early stage of adipogenesis by maintaining preadipocytes in an undifferentiated state. 16 Consequently, at the outset of the differentiation process, Wnt signaling is turned off in order to facilitate expression of PPARg and C/EBPa. 17, 18 An important component of the Wnt pathway is b-catenin, which normally exists in the cytoplasm associated with cytoskeletal elements and its abundance is maintained at a desired level through the ubiquitinproteasome system. Targeting b-catenin for proteasomal degradation is regulated through the phosphorylation of serines and threonines at the N-terminus of the molecule by GSK3b. Inhibition of GSK3b activity by effectors such as Wnt facilitates the accumulation of b-catenin in the cytoplasm and its relocation to the nucleus where it acts as a coactivator of the Tcf/LEF family of transcription factors. The nuclei of preadipocytes contain abundant amounts of b-catenin for at least 2 days poststimulation with the adipogenic inducers, a time coinciding with the activation of a Wnt target gene cyclin D1 and progression of the preadipocytes through the cell cycle. As the cells begin to undergo terminal adipogenesis, there is an extensive downregulation of b-catenin at a post-transcriptional level, which coincides with the induction of PPARg expression. We have recently shown that activation of PPARg with troglitazone directs b-catenin to the proteasome through mechanisms that depend on GSK3b activity. 18 Specifically, we show that activation of PPARg by exposure of Swiss mouse fibroblasts to troglitazone stimulates adipogenesis and a corresponding degradation of bcatenin. Treatment of the cells with LiCl (an inhibitor of GSK3b activity) or MG132 (an inhibitor of the proteasome) prevents this troglitazone-associated downregulation of bcatenin. Furthermore, we also found that a GSK3b-phosphorylation-defective b-catenin in which serine 37 has been modified to an alanine renders b-catenin resistant to the degradatory action of PPARg. Interestingly, expression of the mutant b-catenin in Swiss fibroblasts blocks the expression of adiponectin and C/EBPa in response to the activation of PPARg without blocking the expression of FABP4 (aP2). These observations suggest that there is a crosstalk between bcatenin and PPARg during adipogenesis. If GSK3b activity is maintained at appropriate levels, then PPARg is able to participate in processes that direct b-catenin for degradation in the proteasome and ensure that terminal adipogenesis will occur. If, however, GSK3b activity is greatly attenuated, then b-catenin escapes proteasomal degradation and in that case inhibits expression of PPARg target genes such as adiponectin ( Figure 3 ). In summary, it appears that there are several signaling pathways as well as transcription factors converging on PPARg during terminal adipogenesis to ensure expression of the complete adipogenic program, which includes production of important adipocytokines such as adiponectin. Consequently, the protein components of these pathways regulating PPARg activity are additional targets for the development of therapeutics for the treatment of obesityrelated disorders such as type 2 diabetes. 
